Is This Dividend King a Buy Near Its 52-Week Low?
Even with the rally in the S&P 500 index over the past week, the index is still 20% lower than where it began the year. The state of the global economy, coupled with military conflict in Ukraine, has many stocks trading near their 52-week low.
Down 30% so far in 2022, diversified healthcare company Abbott Laboratories (NYSE: ABT) is one such example. At just 5% above its 52-week low of $93, is Abbott a buy for dividend growth investors? A look at its fundamentals and valuation will help show whether it could fit within a dividend-growth portfolio.
Abbott's products are sold in over 160 countries and used by millions of people each day. They include heart pumps and its FreeStyle Libre diabetes care franchise, COVID-19 rapid tests, products like Similac infant formula and Ensure nutritional shakes, and generic medicines.
Source Fool.com
